ZVSA — ZyVersa Therapeutics, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1859007 ·
Last close
$0.10
Market Cap
$801.5K
52W High
$0.30
52W Low
$0.08
ADV30
3,820
Next earnings
2026-09-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,304,698 | -1,793,381 | 742,223 | 302,660 | 14,866,518 |
| Dec 2025 | 0 | — | -551,858 | -678,572 | 347,901 | 101,778 | 12,734,687 |
| Sep 2025 | 0 | — | -2,104,227 | -19,805,559 | 1,040,260 | 527,978 | 12,765,827 |
| Jun 2025 | 0 | — | -2,044,132 | -2,211,317 | 19,641,111 | 72,086 | 13,541,337 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,141,447
Investing CF
—
Financing CF
$2,832,575
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.97
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,378,318
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-24,814,327
Pretax Income TTM
$-25,340,488
Interest Exp TTM
$526,161
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,844,787 | -24,952,378 | 347,901 | 12,734,687 | -12,386,786 | -5,114,381 |
| Dec 2024 | 0 | -9,136,834 | -9,413,435 | 20,599,414 | 12,082,967 | 8,516,447 | -7,519,534 |
| Dec 2023 | 0 | -14,420,774 | -98,297,946 | 22,114,284 | 11,039,686 | 11,074,598 | -8,720,819 |
| Dec 2022 | 0 | -13,013,064 | -14,047,607 | 118,506,271 | 18,511,943 | 99,994,328 | -1,494,641 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals Plc | $699.4K | $0.68 | — |
| CDT | CDT Equity Inc. | $1.04M | $0.08 | — |
| EVFM | Evofem Biosciences, Inc. | $1.06M | $0.01 | — |
| SKVI | SKINVISIBLE, INC. | $1.09M | $0.20 | — |
| GSAC | GELSTAT CORP | $1.12M | $0.00 | — |
News headlines (Yahoo Finance, 1h cache)
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
2026-03-31 21:05 · Yahoo
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-13 20:55 · Yahoo
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
2025-11-19 21:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.